{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T06:34:19Z","timestamp":1775889259449,"version":"3.50.1"},"reference-count":46,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":1645,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1124\/jpet.120.265538","type":"journal-article","created":{"date-parts":[[2020,4,29]],"date-time":"2020-04-29T00:45:25Z","timestamp":1588121125000},"page":"211-222","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"title":["Parsaclisib Is a Next-Generation Phosphoinositide 3-Kinase \u03b4 Inhibitor with Reduced Hepatotoxicity and Potent Antitumor and Immunomodulatory Activities in Models of B-Cell Malignancy"],"prefix":"10.1016","volume":"374","author":[{"given":"Niu","family":"Shin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Stubbs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Holly","family":"Koblish","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eddy W.","family":"Yue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maxim","family":"Soloviev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brent","family":"Douty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathy He","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingming","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gengjie","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leslie","family":"Hall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Hansbury","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sybil","family":"O\u2019Connor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynn","family":"Leffet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Collins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kamna","family":"Katiyar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Waeltz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Collier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun-Long","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanlong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phillip C.C.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy","family":"Burn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryanne","family":"Covington","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharon","family":"Diamond","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dana","family":"Shuey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Swamy","family":"Yeleswaram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Greg","family":"Hollis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Metcalf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenqing","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reid","family":"Huber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Combs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Newton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peggy","family":"Scherle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.120.265538_bib1","doi-asserted-by":"crossref","first-page":"4135","DOI":"10.1158\/0008-5472.CAN-16-1925","article-title":"Enhanced therapeutic efficacy and memory of tumor-specific CD8 T cells by ex vivo PI3K-\u03b4 inhibition","volume":"77","author":"Abu Eid","year":"2017","journal-title":"Cancer Res"},{"key":"10.1124\/jpet.120.265538_bib2","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/nature13444","article-title":"Inactivation of PI(3)K p110\u03b4 breaks regulatory T-cell-mediated immune tolerance to cancer","volume":"510","author":"Ali","year":"2014","journal-title":"Nature"},{"key":"10.1124\/jpet.120.265538_bib3","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1158\/1078-0432.CCR-14-1561","article-title":"The BET bromodomain inhibitor OTX015 affects pathogenetic pathways in preclinical B-cell tumor models and synergizes with targeted drugs","volume":"21","author":"Boi","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1124\/jpet.120.265538_bib4","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/S1470-2045(18)30082-2","article-title":"Umbralisib, a novel PI3K\u03b4 and casein kinase-1\u03b5 inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study","volume":"19","author":"Burris","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1124\/jpet.120.265538_bib5","doi-asserted-by":"crossref","first-page":"E28","DOI":"10.3390\/vaccines4030028","article-title":"Regulatory T cells in the tumor microenvironment and cancer progression: role and therapeutic targeting","volume":"4","author":"Chaudhary","year":"2016","journal-title":"Vaccines (Basel)"},{"key":"10.1124\/jpet.120.265538_bib6","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1091\/mbc.e09-08-0744","article-title":"Essential role of the p110beta subunit of phosphoinositide 3-OH kinase in male fertility","volume":"21","author":"Ciraolo","year":"2010","journal-title":"Mol Biol Cell"},{"key":"10.1124\/jpet.120.265538_bib7","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.3109\/10428194.2015.1022770","article-title":"Management of adverse events associated with idelalisib treatment: expert panel opinion","volume":"56","author":"Coutr\u00e9","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1124\/jpet.120.265538_bib8","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nature08638","article-title":"Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma","volume":"463","author":"Davis","year":"2010","journal-title":"Nature"},{"key":"10.1124\/jpet.120.265538_bib9","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.cell.2011.08.017","article-title":"BET bromodomain inhibition as a therapeutic strategy to target c-Myc","volume":"146","author":"Delmore","year":"2011","journal-title":"Cell"},{"key":"10.1124\/jpet.120.265538_bib10","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1172\/JCI99386","article-title":"PI3K p110\u03b4 inactivation antagonizes chronic lymphocytic leukemia and reverses T cell immune suppression","volume":"129","author":"Dong","year":"2019","journal-title":"J Clin Invest"},{"key":"10.1124\/jpet.120.265538_bib11","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1021\/acsmedchemlett.6b00238","article-title":"Discovery of a selective phosphoinositide-3-kinase (PI3K)-\u03b3 inhibitor (IPI-549) as an immuno-oncology clinical candidate","volume":"7","author":"Evans","year":"2016","journal-title":"ACS Med Chem Lett"},{"key":"10.1124\/jpet.120.265538_bib12","doi-asserted-by":"crossref","first-page":"4161","DOI":"10.4049\/jimmunol.174.7.4161","article-title":"Stable activation of phosphatidylinositol 3-kinase in the T cell immunological synapse stimulates Akt signaling to FoxO1 nuclear exclusion and cell growth control","volume":"174","author":"Fabre","year":"2005","journal-title":"J Immunol"},{"key":"10.1124\/jpet.120.265538_bib13","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1002\/ajh.25228","article-title":"Duvelisib, an oral dual PI3K-\u03b4, \u03b3 inhibitor, shows clinical activity in indolent non-Hodgkin lymphoma in a phase 1 study","volume":"93","author":"Flinn","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1124\/jpet.120.265538_bib14","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1182\/blood-2018-08-867499","article-title":"Parsaclisib, a potent and highly selective PI3K\u03b4 inhibitor, in patients with relapsed or refractory B-cell malignancies","volume":"133","author":"Forero-Torres","year":"2019","journal-title":"Blood"},{"key":"10.1124\/jpet.120.265538_bib15","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1172\/JCI24480","article-title":"Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells","volume":"115","author":"Gattinoni","year":"2005","journal-title":"J Clin Invest"},{"key":"10.1124\/jpet.120.265538_bib16","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1080\/14737140.2017.1285702","article-title":"Clinical use of PI3K inhibitors in B-cell lymphoid malignancies: today and tomorrow","volume":"17","author":"Greenwell","year":"2017","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1124\/jpet.120.265538_bib17","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.jaut.2011.02.006","article-title":"PI3K\u03b4 drives the pathogenesis of experimental autoimmune encephalomyelitis by inhibiting effector T cell apoptosis and promoting Th17 differentiation","volume":"36","author":"Haylock-Jacobs","year":"2011","journal-title":"J Autoimmun"},{"key":"10.1124\/jpet.120.265538_bib18","doi-asserted-by":"crossref","first-page":"4243","DOI":"10.1182\/blood-2006-10-050633","article-title":"Insulin-like growth factor-1 potentiates platelet activation via the IRS\/PI3Kalpha pathway","volume":"110","author":"Hers","year":"2007","journal-title":"Blood"},{"key":"10.1124\/jpet.120.265538_bib19","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1182\/blood-2011-05-352492","article-title":"The phosphoinositide 3\u2032-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia","volume":"118","author":"Hoellenriegel","year":"2011","journal-title":"Blood"},{"key":"10.1124\/jpet.120.265538_bib20","doi-asserted-by":"crossref","first-page":"E699","DOI":"10.1073\/pnas.1108237108","article-title":"PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axis","volume":"108","author":"Ilic","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/jpet.120.265538_bib21","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/nrc2230","article-title":"Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics","volume":"7","author":"Jares","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"10.1124\/jpet.120.265538_bib22","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1182\/blood-2009-03-212191","article-title":"Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival","volume":"114","author":"Johnson","year":"2009","journal-title":"Blood"},{"key":"10.1124\/jpet.120.265538_bib23","doi-asserted-by":"crossref","unstructured":"Kirkwood JM, Lannotti N, Cho D, O\u2019Day S, Gibney G, Hodi S, Munster P, Hoyle P, Owens S, Smith M (2018) Effect of JAK\/STAT or PI3K\u03b4 plus PD-1 inhibition on the tumor microenvironment: biomarker results from a phase 1b study in patients with advanced solid tumors, in Proceedings of the 109th Annual Meeting of the American Association for Cancer Research; 2018 April 14\u201318; Chicago, IL. pp ACT176.","DOI":"10.1158\/1538-7445.AM2018-CT176"},{"key":"10.1124\/jpet.120.265538_bib24","doi-asserted-by":"crossref","first-page":"e0199108","DOI":"10.1371\/journal.pone.0199108","article-title":"Preclinical characterization of INCB053914, a novel pan-PIM kinase inhibitor, alone and in combination with anticancer agents, in models of hematologic malignancies","volume":"13","author":"Koblish","year":"2018","journal-title":"PLoS One"},{"key":"10.1124\/jpet.120.265538_bib25","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.celrep.2012.02.007","article-title":"PI3K-Akt-mTORC1-S6K1\/2 axis controls Th17 differentiation by regulating Gfi1 expression and nuclear translocation of ROR\u03b3","volume":"1","author":"Kurebayashi","year":"2012","journal-title":"Cell Rep"},{"key":"10.1124\/jpet.120.265538_bib26","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1182\/blood-2016-03-707133","article-title":"Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity","volume":"128","author":"Lampson","year":"2016","journal-title":"Blood"},{"key":"10.1124\/jpet.120.265538_bib27","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1182\/blood-2010-03-275305","article-title":"CAL-101, a p110\u03b4 selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability","volume":"117","author":"Lannutti","year":"2011","journal-title":"Blood"},{"key":"10.1124\/jpet.120.265538_bib28","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1038\/nm.2402","article-title":"Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway-dependent and PI3K pathway-independent mechanisms","volume":"17","author":"Liu","year":"2011","journal-title":"Nat Med"},{"key":"10.1124\/jpet.120.265538_bib29","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/0092-8674(89)90174-8","article-title":"bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation","volume":"57","author":"McDonnell","year":"1989","journal-title":"Cell"},{"key":"10.1124\/jpet.120.265538_bib30","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1126\/science.1073560","article-title":"Impaired B and T cell antigen receptor signaling in p110\u03b4 PI 3-kinase mutant mice","volume":"297","author":"Okkenhaug","year":"2002","journal-title":"Science"},{"key":"10.1124\/jpet.120.265538_bib31","doi-asserted-by":"crossref","first-page":"5122","DOI":"10.4049\/jimmunol.177.8.5122","article-title":"The p110\u03b4 isoform of phosphoinositide 3-kinase controls clonal expansion and differentiation of Th cells","volume":"177","author":"Okkenhaug","year":"2006","journal-title":"J Immunol"},{"key":"10.1124\/jpet.120.265538_bib32","doi-asserted-by":"crossref","first-page":"6598","DOI":"10.4049\/jimmunol.177.10.6598","article-title":"Cutting edge: the phosphoinositide 3-kinase p110 \u03b4 is critical for the function of CD4+CD25+Foxp3+ regulatory T cells","volume":"177","author":"Patton","year":"2006","journal-title":"J Immunol"},{"key":"10.1124\/jpet.120.265538_bib33","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1182\/blood-2017-10-812701","article-title":"Phase 1 study of the PI3K\u03b4 inhibitor INCB040093 \u00b1 JAK1 inhibitor itacitinib in relapsed\/refractory B-cell lymphoma","volume":"132","author":"Phillips","year":"2018","journal-title":"Blood"},{"key":"10.1124\/jpet.120.265538_bib34","doi-asserted-by":"crossref","first-page":"256","DOI":"10.3389\/fimmu.2012.00256","article-title":"Selective inhibitors of phosphoinositide 3-kinase delta: modulators of B-cell function with potential for treating autoimmune inflammatory diseases and B-cell malignancies","volume":"3","author":"Puri","year":"2012","journal-title":"Front Immunol"},{"key":"10.1124\/jpet.120.265538_bib35","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.humpath.2018.11.015","article-title":"p53 expression in large B-cell lymphomas with MYC extra copies and CD99 expression in large B-cell lymphomas in relation to MYC status","volume":"86","author":"Richardson","year":"2019","journal-title":"Hum Pathol"},{"key":"10.1124\/jpet.120.265538_bib36","doi-asserted-by":"crossref","first-page":"4612","DOI":"10.4049\/jimmunol.1103173","article-title":"Blockade of phosphatidylinositol 3-kinase PI3K\u03b4 or PI3K\u03b3 reduces IL-17 and ameliorates imiquimod-induced psoriasis-like dermatitis","volume":"189","author":"Roller","year":"2012","journal-title":"J Immunol"},{"key":"10.1124\/jpet.120.265538_bib37","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1182\/blood-2006-04-015586","article-title":"Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma","volume":"108","author":"Rudelius","year":"2006","journal-title":"Blood"},{"key":"10.1124\/jpet.120.265538_bib38","doi-asserted-by":"crossref","first-page":"E348","DOI":"10.1002\/ijc.26423","article-title":"High Myc activity is an independent negative prognostic factor for diffuse large B cell lymphomas","volume":"131","author":"Schrader","year":"2012","journal-title":"Int J Cancer"},{"key":"10.1124\/jpet.120.265538_bib39","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1124\/jpet.117.244947","article-title":"INCB040093 is a novel PI3K\u03b4 inhibitor for the treatment of B cell lymphoid malignancies","volume":"364","author":"Shin","year":"2018","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.120.265538_bib40","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1182\/blood-2009-07-232330","article-title":"PI3K p110\u03b4 regulates T-cell cytokine production during primary and secondary immune responses in mice and humans","volume":"115","author":"Soond","year":"2010","journal-title":"Blood"},{"key":"10.1124\/jpet.120.265538_bib41","doi-asserted-by":"crossref","first-page":"3958","DOI":"10.4049\/jimmunol.1301533","article-title":"Innate PI3K p110\u03b4 regulates Th1\/Th17 development and microbiota-dependent colitis","volume":"192","author":"Steinbach","year":"2014","journal-title":"J Immunol"},{"key":"10.1124\/jpet.120.265538_bib42","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1158\/1078-0432.CCR-18-0098","article-title":"The novel bromodomain and extraterminal domain inhibitor INCB054329 induces vulnerabilities in myeloma cells that inform rational combination strategies","volume":"25","author":"Stubbs","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1124\/jpet.120.265538_bib43","doi-asserted-by":"crossref","first-page":"13057","DOI":"10.1073\/pnas.0802655105","article-title":"PTEN-deficient cancers depend on PIK3CB","volume":"105","author":"Wee","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/jpet.120.265538_bib44","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.bbrc.2005.12.025","article-title":"Correlation of PIK3Ca mutations with gene expression and drug sensitivity in NCI-60 cell lines","volume":"340","author":"Whyte","year":"2006","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1124\/jpet.120.265538_bib45","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1021\/acsmedchemlett.9b00334","article-title":"INCB050465 (parsaclisib), a novel next-generation inhibitor of phosphoinositide 3-kinase delta (PI3K\u03b4)","volume":"10","author":"Yue","year":"2019","journal-title":"ACS Med Chem Lett"},{"key":"10.1124\/jpet.120.265538_bib46","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1073\/pnas.1205299110","article-title":"Genetic heterogeneity of diffuse large B-cell lymphoma","volume":"110","author":"Zhang","year":"2013","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524257943?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524257943?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.120.265538","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T16:53:20Z","timestamp":1740675200000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524257943"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["S0022356524257943"],"URL":"https:\/\/doi.org\/10.1124\/jpet.120.265538","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Parsaclisib Is a Next-Generation Phosphoinositide 3-Kinase \u03b4 Inhibitor with Reduced Hepatotoxicity and Potent Antitumor and Immunomodulatory Activities in Models of B-Cell Malignancy","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.120.265538","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 by The Author(s)","name":"copyright","label":"Copyright"}]}}